IP Library › Granted Patent US 11,840,560
Granted Patent B2
US 11,840,560 · App. 18/099,282 · Granted Dec 12, 2023

Prodrugs and uses thereof

Inventors: Patrick James Knerr (Plainfield, IN); Brian Patrick Finan (Indianapolis, IN)
Assignee: Novo Nordisk A/S
C07K14/605
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,840,560
App. No.
18/099,282
Granted
Dec 12, 2023
Kind
B2
Abstract

Prodrug compounds of GLP-1/GIP receptor co-agonists are provided wherein the GLP-1/GIP receptor co-agonists have been modified by the linkage of a dipeptide to the GLP-1/GIP receptor co-agonist through an amide bond. The prodrugs disclosed herein have extended half-lives and are converted to the active GLP-1/GIP receptor co-agonist at physiological conditions through a non-enzymatic reaction driven by chemical instability.

Claims (2)

1. A compound of

or a pharmaceutical acceptable salt, ester or amide thereof.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 31, 2023
From: KNERR, PATRICK JAMES; FINAN, BRIAN PATRICK
To: NOVO NORDISK A/S
Reel/Frame 062547/0246 →
Priority Claims (1)
EP 22154309 · Jan 31, 2022 · regional
Continuity (2)
Provisional Application 63301311 · Jan 20, 2022
Related Publication 20230227521A1 · Jul 20, 2023